Formycon AG (FRA:FYB)
25.10
+0.10 (0.40%)
Last updated: Aug 15, 2025
Formycon AG Employees
Formycon AG had 250 employees as of December 31, 2024. The number of employees increased by 12 or 5.04% compared to the previous year.
Employees
250
Change (1Y)
12
Growth (1Y)
5.04%
Revenue / Employee
€207,112
Profits / Employee
€679,080
Market Cap
441.42M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Siemens Energy AG | 98,000 |
Rheinmetall AG | 28,539 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Deutsche Bank Aktiengesellschaft | 89,753 |
Formycon AG News
- 17 days ago - EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025 - Wallstreet:Online
- 4 weeks ago - EQS-AFR: Formycon AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] - Wallstreet:Online
- 5 weeks ago - EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda biosimilar candidate FYB206 - Wallstreet:Online
- 6 weeks ago - EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta (ranibizumab) across Sub-Saharan Africa - Wallstreet:Online
- 7 weeks ago - EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond - Wallstreet:Online
- 7 weeks ago - EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara biosimilar FYB202 (ustekinumab) under the brand name Fymskina in Germany - Wallstreet:Online
- 7 weeks ago - EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in the United States and Canada - Wallstreet:Online
- 7 weeks ago - EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period - Wallstreet:Online